Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glioblastoma Multiforme: early-phase trial registry
37 of 89 indexed Glioblastoma Multiforme trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #154 of 28,707 conditions by registered trial count.
89 US clinical trials · 37 currently recruiting · #154 of 28,707 conditions by registered trial count
Glioblastoma Multiforme: 89 US clinical trials tracked, 37 recruiting.
Glioblastoma Multiforme is the subject of 89 registered US clinical trials on ClinicalTrials.gov, 37 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 74 in Phase 1-2 (earlier-stage). The most active sponsor is Northwell Health, running 6 of these trials.
Enrollment posture brief
Registry condition glioblastoma-multiforme
OPEN 37 | RECR 42% | LATE 1 | EARLY 74 | RANK #154 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Post Traumatic Stress Disorder (42% recruiting · 265 trials)
Glioblastoma Multiforme lists 37 open slots (42% of 89 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Glioblastoma Multiforme on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Glioblastoma Multiforme recruits in line with its size-band peers.
37 of 89 indexed trials (41.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Glioblastoma Multiforme trials is spread across many organizations.
Northwell Health accounts for 6 of 89 trials (6.7%). 61 distinct sponsors appear on at least one study for this condition label.
-
Most Glioblastoma Multiforme trials plan to enrol fewer than 100 people.
Median target enrolment is 41 among the 89 trials that report a genuine target (sentinel values excluded). 72 of those (80.9%) plan for fewer than 100 participants.
-
Glioblastoma Multiforme research is mostly interventional.
80 interventional and 9 observational studies make up this index (89.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
89 total, page 1 of 2
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
Jasper Gerritsen
NCT06146738
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
Jasper Gerritsen
NCT06146725
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Apollomics
NCT03175224
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Jasper Gerritsen
NCT06283927
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Northwell Health
NCT05271240
Targeted Pediatric High-Grade Glioma Therapy
Nationwide Children's Hospital
NCT05839379
Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme
National Cancer Institute (NCI)
NCT00083512
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Baptist Health South Florida
NCT06991101
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
Cedars-Sinai Medical Center
NCT05708352
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
NCT05843253
Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue
Baptist Health South Florida
NCT05756985
Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning
Washington University School of Medicine
NCT05864976
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
VBI Vaccines
NCT03382977
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Orbus Therapeutics
NCT05879367
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
David Baskin MD
NCT03596086
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
Northwell Health
NCT01269853
Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells
Jonsson Comprehensive Cancer Center
NCT06059690
Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05083754
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Neonc Technologies
NCT02704858
Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma
Washington University School of Medicine
NCT05281731
Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
UNC Lineberger Comprehensive Cancer Center
NCT05366179
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Boston Scientific Corporation
NCT05303467
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
Northwell Health
NCT05954858
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
University of Arizona
NCT06814496
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Aveta Biomics
NCT06011109
Loupe-Based Intraoperative Fluorescence Imaging
Guoqiang Yu
NCT04780009
Study of Pembrolizumab and M032 (NSC 733972)
University of Alabama at Birmingham
NCT05084430
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Northwestern University
NCT05864534
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
NCT03911388
Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
University of Miami
NCT05956821
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
Henry Ford Health System
NCT05686798
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
Leland Metheny
NCT05052957
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Nationwide Children's Hospital
NCT06333899
Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
Stony Brook University
NCT05423210
Sonodynamic Therapy in Patients With Recurrent GBM
Shayan Moosa, MD
NCT06039709
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Chirag G. Patil
NCT04977375
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Northwell Health
NCT05979064
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM
NovoCure
NCT04471844
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
NCT04478279
Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM
University of Sydney
NCT04195139
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
Nader Sanai
NCT05182905
A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme
Bryan Allen
NCT02344355
A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
NuvOx
NCT03862430
Surgical Nivolumab And Ipilimumab For Recurrent GBM
Patrick Wen, MD
NCT04606316
Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02177578
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
Northwestern University
NCT04528680
A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
Katmai Pharmaceuticals
NCT05222802
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
BPGbio
NCT04752813
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients
Nader Sanai
NCT02933736
Study of Pamiparib in Newly Diagnosed and rGBM
Nader Sanai
NCT04614909
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 26 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Glioblastoma Multiforme records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Glioblastoma Multiforme trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Glioblastoma Multiforme page
89 registered trials, 37 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 37 Glioblastoma Multiforme trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Northwell Health sponsors the most Glioblastoma Multiforme trials on record, review their full trial history before evaluating a specific study. See Northwell Health's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glioblastoma Multiforme condition card totals 89 registered trials; most-linked intervention Temozolomide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.